2 citations,
September 2023 in “Frontiers in molecular biosciences” Inducing ferroptosis in hepatic stellate cells is crucial for treating liver fibrosis.
3 citations,
January 2024 in “Liver International” Targeting thyroid hormone receptor α in liver cells may help treat liver fibrosis.
18 citations,
February 2022 in “Cell Death Discovery” The study demonstrates that ECM1-modified hair follicle-derived mesenchymal stem cells (ECM1-HF-MSCs) can effectively treat liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway, which is crucial in liver fibrosis. Using a mouse model of liver cirrhosis induced by CCl4, the research shows that ECM1-HF-MSCs improve liver function and reduce liver injury more effectively than naïve HF-MSCs. These modified cells migrate to the liver, express hepatocyte-specific markers, and significantly inhibit hepatic stellate cell activation. The findings suggest that ECM1-HF-MSCs offer a promising therapeutic approach for liver cirrhosis through genetic modification.
4 citations,
February 2022 in “PeerJ” Hair follicle stem cell transplants can reverse liver cirrhosis by blocking harmful cell activation.
2 citations,
May 2023 in “Life” Plumbagin may help protect cells, reduce inflammation, and has potential for treating various diseases, but more research is needed.